While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Subscribe To Our Newsletter & Stay Updated
